ECUR-506 maker DTIL iECURE to present OTC-HOPE trial data at SSIEM
DTIL iECURE plans to present clinical data from its ongoing OTC-HOPE trial of ECUR-506 in neonatal-onset ornithine transcarbamylase deficiency at the SSIEM Annual Symposium.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.